Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ · Healthcare
Black Diamond Therapeutics, Inc. Shareholder Equity 2018–2025
Black Diamond Therapeutics, Inc. annual/quarterly shareholder equity history from 2018 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Black Diamond Therapeutics, Inc. shareholder equity for the quarter ending December 31, 2025 were 112.2M, a 34.73% increase year-over-year.
- Black Diamond Therapeutics, Inc. shareholder equity for 2025 were 112.2M, a 34.73% increase from 2024.
- Black Diamond Therapeutics, Inc. shareholder equity for 2024 were 83.3M, a 72.94% decrease from 2020.
- Black Diamond Therapeutics, Inc. shareholder equity for 2020 were 307.8M, a 752.62% decrease from 2019.
- Black Diamond Therapeutics, Inc. shareholder equity for 2019 were -47.2M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Black Diamond Therapeutics, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $112 |
| 2024 | $83 |
| 2020 | $308 |
| 2019 | $-47 |
| 2018 | $-16 |
| Black Diamond Therapeutics, Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $112 |
| 2024-12-31 | $83 |
| 2020-12-31 | $308 |
| 2019-12-31 | $-47 |
| 2018-12-31 | $-16 |
Black Diamond Therapeutics, Inc. Shareholder Equity — FAQ
Black Diamond Therapeutics, Inc. (BDTX) shareholder equity over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BDTX's shareholder equity history?
The chart and table above show Black Diamond Therapeutics, Inc.'s shareholder equity by year and by quarter, including the growth rate.